HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of topical application of the platelet-activating factor-antagonist, Ro 24-0238, in psoriasis vulgaris--a clinical and immunohistochemical study.

Abstract
Platelet-activating factor (PAF) is considered to be one of the most potent lipid mediators in allergic and inflammatory reactions. Suggestions that PAF is produced by cutaneous cells, and cells infiltrating the skin from the blood, have been reported. PAF has been identified in allergic cutaneous reactions and also in psoriatic lesions. The biological activity of PAF is thought to be mediated by cell membrane receptors. Studies revealed that PAF-antagonists can be active in animal models of cutaneous inflammation. In humans PAF-antagonists showed minimal therapeutic improvement in studies of antigen-induced cutaneous responses in atopic subjects. No data are available on the effects of PAF-antagonists in psoriasis. The objective of this study was to investigate the effect of a potent PAF-antagonist (Ro 24-0238, 10% solution in diethylene glycol monoethyl ether) in 10 patients with chronic plaque psoriasis, a placebo-controlled double-blind study. Clinical response was evaluated and markers of inflammation, differentiation and proliferation were studied immunohistochemically on punch biopsies taken from actively treated and placebo-treated lesions, before and after treatment. This study demonstrated that a 10% solution of the PAF-antagonist Ro 24-0238 was not effective at the clinical or cell biological level after a 4-week treatment period. The most likely explanation for these negative observations is that PAF is not a significant factor in the pathogenesis of psoriasis.
AuthorsM E Elbers, M J Gerritsen, P C van de Kerkhof
JournalClinical and experimental dermatology (Clin Exp Dermatol) Vol. 19 Issue 6 Pg. 453-7 (Nov 1994) ISSN: 0307-6938 [Print] England
PMID7889665 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Platelet Activating Factor
  • Polyunsaturated Alkamides
  • Pyridines
  • Ro 24-0238
Topics
  • Adult
  • Chronic Disease
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Activating Factor (antagonists & inhibitors)
  • Polyunsaturated Alkamides
  • Psoriasis (drug therapy, metabolism, pathology)
  • Pyridines (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: